KYTX News & Events

Kyverna Therapeutics files $300M mixed securities shelf

Kyverna Therapeutics announced the appointments of Sravan Emany and Andrew Miller, Ph.D. to its Board of Directors. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped down from the Board. Emany currently serves as the CFO of Beam Therapeutics. Most recently, Dr. Miller was the Founder and President of R&D at Karuna Therapeutics.

Kyverna Therapeutics announced the appointment of Mayo Pujols as its Chief Technology Officer, CTO, effective February 9, 2026. Most recently, Pujols served as Chief Operating Officer of Castle Creek Biosciences